BioLeap Raises $5 Million
BioLeap Inc., a New Hope, Penn.-based drug developer that utilizes computational fragment-based design technology, has raised $5 million in Series A funding from Adams Capital Management and Quaker BioVentures.
12 January 2010•4 mins read
